Free Trial

Codexis Q1 2023 Earnings Report

Codexis logo
$5.28 +0.16 (+3.13%)
(As of 12/20/2024 05:31 PM ET)

Codexis EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.29
Beat/Miss
Missed by -$0.05
One Year Ago EPS
-$0.13

Codexis Revenue Results

Actual Revenue
$12.98 million
Expected Revenue
$14.09 million
Beat/Miss
Missed by -$1.11 million
YoY Revenue Growth
-63.30%

Codexis Announcement Details

Quarter
Q1 2023
Time
After Market Closes
The #1 Coin for November 2024 (Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

Codexis Earnings Headlines

Codexis Announces New Employment Inducement Grants
The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
Cantor Fitzgerald Keeps Their Buy Rating on Codexis (CDXS)
Stifel Nicolaus Remains a Buy on Codexis (CDXS)
See More Codexis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Codexis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Codexis and other key companies, straight to your email.

About Codexis

Codexis (NASDAQ:CDXS) discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

View Codexis Profile

More Earnings Resources from MarketBeat

Upcoming Earnings